QQQ   386.84 (-0.76%)
AAPL   188.79 (-0.31%)
MSFT   375.88 (-0.78%)
META   324.55 (-2.30%)
GOOGL   131.63 (-2.49%)
AMZN   144.80 (-1.04%)
TSLA   239.71 (-1.81%)
NVDA   466.25 (-3.15%)
NIO   7.21 (+0.42%)
BABA   74.51 (-0.21%)
AMD   120.24 (-2.91%)
T   16.49 (+1.17%)
F   10.22 (-3.49%)
MU   75.31 (-1.80%)
CGC   0.56 (+0.05%)
GE   120.91 (+1.72%)
DIS   92.66 (+0.17%)
AMC   6.73 (-6.14%)
PFE   30.36 (+0.93%)
PYPL   57.72 (-0.43%)
XOM   102.41 (+0.07%)
QQQ   386.84 (-0.76%)
AAPL   188.79 (-0.31%)
MSFT   375.88 (-0.78%)
META   324.55 (-2.30%)
GOOGL   131.63 (-2.49%)
AMZN   144.80 (-1.04%)
TSLA   239.71 (-1.81%)
NVDA   466.25 (-3.15%)
NIO   7.21 (+0.42%)
BABA   74.51 (-0.21%)
AMD   120.24 (-2.91%)
T   16.49 (+1.17%)
F   10.22 (-3.49%)
MU   75.31 (-1.80%)
CGC   0.56 (+0.05%)
GE   120.91 (+1.72%)
DIS   92.66 (+0.17%)
AMC   6.73 (-6.14%)
PFE   30.36 (+0.93%)
PYPL   57.72 (-0.43%)
XOM   102.41 (+0.07%)
QQQ   386.84 (-0.76%)
AAPL   188.79 (-0.31%)
MSFT   375.88 (-0.78%)
META   324.55 (-2.30%)
GOOGL   131.63 (-2.49%)
AMZN   144.80 (-1.04%)
TSLA   239.71 (-1.81%)
NVDA   466.25 (-3.15%)
NIO   7.21 (+0.42%)
BABA   74.51 (-0.21%)
AMD   120.24 (-2.91%)
T   16.49 (+1.17%)
F   10.22 (-3.49%)
MU   75.31 (-1.80%)
CGC   0.56 (+0.05%)
GE   120.91 (+1.72%)
DIS   92.66 (+0.17%)
AMC   6.73 (-6.14%)
PFE   30.36 (+0.93%)
PYPL   57.72 (-0.43%)
XOM   102.41 (+0.07%)
QQQ   386.84 (-0.76%)
AAPL   188.79 (-0.31%)
MSFT   375.88 (-0.78%)
META   324.55 (-2.30%)
GOOGL   131.63 (-2.49%)
AMZN   144.80 (-1.04%)
TSLA   239.71 (-1.81%)
NVDA   466.25 (-3.15%)
NIO   7.21 (+0.42%)
BABA   74.51 (-0.21%)
AMD   120.24 (-2.91%)
T   16.49 (+1.17%)
F   10.22 (-3.49%)
MU   75.31 (-1.80%)
CGC   0.56 (+0.05%)
GE   120.91 (+1.72%)
DIS   92.66 (+0.17%)
AMC   6.73 (-6.14%)
PFE   30.36 (+0.93%)
PYPL   57.72 (-0.43%)
XOM   102.41 (+0.07%)

Icosavax Stock Price, News & Analysis (NASDAQ:ICVX)

$9.94
-0.29 (-2.83%)
(As of 02:34 PM ET)
Compare
Today's Range
$9.92
$10.82
50-Day Range
$5.95
$11.24
52-Week Range
$3.09
$16.45
Volume
575,292 shs
Average Volume
230,907 shs
Market Capitalization
$497.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.50

Icosavax MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
166.6% Upside
$26.50 Price Target
Short Interest
Bearish
5.49% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.81mentions of Icosavax in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.20) to ($2.21) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

656th out of 949 stocks

Biological Products, Except Diagnostic Industry

109th out of 163 stocks


ICVX stock logo

About Icosavax Stock (NASDAQ:ICVX)

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington.

ICVX Stock Price History

ICVX Stock News Headlines

Icosavax (NASDAQ:ICVX) Trading 6.1% Higher
Why Microsoft Just Placed A Huge Bet On Nuclear
Even with aggressive expansion and acquisition of solar and wind farms, renewable energy isn’t anywhere close to providing the energy that Microsoft demands.
Icosavax initiated with a Buy at Guggenheim
TD Cowen Keeps Their Buy Rating on Icosavax (ICVX)
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Aura Biosciences GAAP EPS of -$0.48
Jefferies Reaffirms Their Buy Rating on Icosavax (ICVX)
Why Shares of Icosavax Jumped on Tuesday
See More Headlines
Receive ICVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Icosavax and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
11/30/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/04/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ICVX
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$26.50
High Stock Price Target
$28.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+159.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-91,760,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$580,000.00
Book Value
$4.64 per share

Miscellaneous

Free Float
34,767,000
Market Cap
$512.42 million
Optionable
Not Optionable
Beta
0.45
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Adam K. Simpson (Age 47)
    President, CEO, Co-Founder & Director
    Comp: $855.95k
  • Mr. Niranjan Kanesa-thasan M.D. (Age 62)
    Chief Medical Officer
    Comp: $641.55k
  • Dr. Cassia Cearley Ph.D. (Age 40)
    Treasurer & Chief Business Officer
    Comp: $632.15k
  • Mr. Neil King Ph.D.
    Chair of Scientific Advisory Board & Co-Founder
  • Dr. David Baker M.D.
    Ph.D., Co-founder & Member of Scientific Advisory Board
  • Mr. Thomas Joseph Russo C.F.A. (Age 51)
    Chief Financial Officer
    Comp: $525.27k
  • Ms. Jennifer Raymond
    Senior Vice President of Technical Operations
  • Ms. Elizabeth Bekiroglu (Age 53)
    General Counsel & Corporate Secretary
    Comp: $230.74k
  • Ms. Lori Stewart
    Senior Vice President of People & Culture
  • Dr. Ami Shah Brown MPH
    Ph.D., Senior Vice President of Regulatory Affairs














ICVX Stock Analysis - Frequently Asked Questions

Should I buy or sell Icosavax stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icosavax in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ICVX shares.
View ICVX analyst ratings
or view top-rated stocks.

What is Icosavax's stock price target for 2024?

3 brokers have issued 12-month price objectives for Icosavax's stock. Their ICVX share price targets range from $25.00 to $28.00. On average, they anticipate the company's share price to reach $26.50 in the next twelve months. This suggests a possible upside of 166.6% from the stock's current price.
View analysts price targets for ICVX
or view top-rated stocks among Wall Street analysts.

How have ICVX shares performed in 2023?

Icosavax's stock was trading at $7.94 at the beginning of the year. Since then, ICVX shares have increased by 25.2% and is now trading at $9.94.
View the best growth stocks for 2023 here
.

When is Icosavax's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our ICVX earnings forecast
.

How were Icosavax's earnings last quarter?

Icosavax, Inc. (NASDAQ:ICVX) issued its quarterly earnings data on Monday, November, 15th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.81. The company had revenue of $1.83 million for the quarter, compared to analyst estimates of $3.30 million.

What ETFs hold Icosavax's stock?

ETFs with the largest weight of Icosavax (NASDAQ:ICVX) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM) and Fidelity Disruptive Medicine ETF (FMED).

When did Icosavax IPO?

(ICVX) raised $150 million in an IPO on Thursday, July 29th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share.

Who are Icosavax's major shareholders?

Icosavax's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (10.90%), Citigroup Inc. (0.63%), Northern Trust Corp (0.54%), Barclays PLC (0.40%), Bank of New York Mellon Corp (0.18%) and GSA Capital Partners LLP (0.05%). Insiders that own company stock include Adam K Simpson, Cassia Cearley, Charles E Richardson, Douglas Holtzman, Elizabeth Bekiroglu, Mark Mcdade, Niranjan Kanesa-Thasan, Ra Capital Management, LP and Thomas Joseph Russo.
View institutional ownership trends
.

How do I buy shares of Icosavax?

Shares of ICVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ICVX) was last updated on 11/30/2023 by MarketBeat.com Staff

My Account -